The Sinnett Lab develops and assesses gene therapies for rare neurodevelopmental disorders.

Minassian Lab has been involved in the identification and co-discovery of the causative gene mutations in over 20 different childhood neurological diseases. 

Our research focuses on how the conserved signaling pathways that underlie normal skin development are altered during the development of non-melanoma skin cancers and inflammatory skin disease.

The research interests of the Lux Lab lie in the development of novel nanomedicine platforms to diagnose and treat disease in vivo noninvasively.

The Bailey lab focuses on developing gene therapies for neurological disorders. We work on monogenetic pediatric disorders, including SLC13A5 epileptic encephalopathy, multiple sulfatase deficiency, Charcot Marie Tooth disease type 4J, giant axonal neuropathy and ECHS1 deficiency.

Dr. Gray is overseeing one of the nation’s few facilities that manufactures a special type of gene-delivering virus for patient use.

Located in the Department of Ophthalmology, the Wert laboratory studies the post-mitotic neuronal cells of the retina, particularly the photoreceptor cells. Our goal is to discover and understand the mechanisms underlying retinal degenerative disease, and to provide novel therapeutics for these complex degenerative disorders using gene therapy and genome engineering technologies, human stem cell transplantations, and metabolic rescue.

Our lab works with murine disease models and employs Biochemistry, Molecular and Cell Biology to investigate brain glycogen metabolism and related neurodegenerative diseases.